Create Medicines
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
300 Technology Sq Ste 203, Cambridge, Ma...Website
www.createmedicines.comRevenue
$9.7 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
2
1
1
1
1
1
About Create Medicines
CREATE Medicines is a clinical-stage biotechnology company developing in vivo immune programming therapies using its proprietary mRNA-LNP platform. The company focuses on engineering immune cells directly inside the body, including T cells, NK cells, and myeloid cells, to create scalable, repeat-dose, off-the-shelf immunotherapies. Its pipeline targets oncology and autoimmune diseases through RNA based CAR approaches designed to improve accessibility, reduce complexity, and enable programmable immune responses for patients.Explore more
Create Medicines Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Create Medicines your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Create Medicines had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Create Medicines launches new products
Check if Create Medicines has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Create Medicines recently announced quarterly report
Funding: Get notified immidiatlly once Create Medicines has new funding data
Check out if Create Medicines is spiking on competitors!
Create Medicines, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Create Medicines
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Create Medicines
Find more new buyers
Company Profile Activity
Activity Insights
Create Medicines is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Create Medicines is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Create Medicines.
Create Medicines financials insights
Gather financial insights about Create Medicines, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Seed
$12M
2026
Series B
$122M
Most Recent Scoops
Funding
Funding
Event
Product Marketing, Events, Sales, Laboratory Operations, Pharmaceuticals, Field /Outside Sales, Clinical Operations, Field Marketing, Healthcare Operations, Operations
Event
Product Marketing, Events, Sales, Laboratory Operations, Pharmaceuticals, Field /Outside Sales, Clinical Operations, Field Marketing, Healthcare Operations, Operations
Event
Events, Engineering, Sales, Bioengineering, Laboratory Operations, Pharmaceuticals, Field /Outside Sales, Clinical Operations, Field Marketing, Operations
Executive Move
Executive Moves, Board of Directors
Create Medicines News & Media
CREATE Medicines Receives Approval to Initiate First-in-Human Phase 1/2 Clinical Trial of In Vivo CAR-T Candidate CRT-402 for Autoimmune Diseases
Australian HREC approval clears the initiation of CREATE's first-in-human Phase 1/2 study evaluating CRT-402 in patients with systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and idiopathic inflammatory myopathies (IIM). HREC approval represents the final regulatory step...CREATE Medicines Strengthens Clinical and Scientific Advisory Board with Appointment of Georg Schett, MD, Margrit Wiesendanger, MD, PhD, and Christopher Jewell, PhD
Appointments come as CREATE advances CRT-402, its lead in vivo CD19 CAR-T program, to clinical development for B cell-driven autoimmune disease CAMBRIDGE, Mass., May 14, 2026 /PRNewswire/ -- CREATE Medicines, Inc. ("CREATE"), a clinical-stage biotechnology company pioneering in vivo...CREATE Medicines Announces $122 Million Series B Financing to Advance In Vivo CAR Pipeline in Autoimmune Disease and Oncology
Financing to support advancement of CREATE's repeat dose capable CD19 targeted in vivo CAR-T therapy for autoimmune disease into the clinic, expansion of its dual CAR CD19 x BCMA program, and continued progress across the oncology portfolio Round co-led by existing investors Newpath...CREATE Medicines Doses First Patient in Phase 1/2 Study of MT-304, a First-in-Class Multi-immune In Vivo CAR Therapy Targeting HER2-Positive Solid Tumors
Validates platform's ability to rapidly iterate across immune cell types Leverages novel NK and myeloid co-programming architecture to deliver coordinated immune activation Powered by CREATE's proprietary in vivo CAR clinical dataset, the industry's largest to date CAMBRIDGE, Mass., April...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Create Medicines
Sign Up For FreeTo access detailed company insights
CREATE Medicines is a clinical-stage biotechnology company developing in vivo immune programming therapies using its proprietary mRNA-LNP platform. The company focuses on engineering immune cells directly inside the body, including T cells, NK cells, and myeloid cells, to create scalable, repeat-dose, off-the-shelf immunotherapies. Its pipeline tar... Read More
